The new reagents include the first-ever commercially available synthetic single guide RNAs for CRISPRi, as well as a patent-pending, dCas9-SALL1-SDS3 repressor available in mRNA and lentiviral ...

A single “best solution ... for improved in vivo transfection methods, especially for RNA interference,” she added. “To advance as a therapeutic, RNAi reagents must be able to reliably ...

In the case of chemical delivery methods, the reagent forms a complex with the nucleic acid to enhance contact with the cell membrane. The ability to successfully transfect a cell varies by cell type, ...